From Hallelujah To Headwind: Pfizer's COVID-19 Franchise Hits The Downturn
Executive Summary
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.
You may also be interested in...
Pfizer Cost Improvement Program Depends On COVID Outlook
If COVID-19 product sales don’t meet assumptions this fall, the company said it will consider a cost reduction program to better align costs with future revenue projections.
Pfizer/Astellas Take Off On New Xtandi Expansion With EMBARK Data
Data from the Phase III EMBARK study showed a significant improvement for the drug both in combination with leuprolide and as a monotherapy in reducing risk of metastasis or death in nmHSPC.
Phase III Results Could Boost Pfizer Revenue Ahead Of Xtandi’s Exclusivity Loss
Pfizer and Astellas announced positive topline Phase III results in non-metastatic prostate cancer for Xtandi, one of the top-selling drugs in Pfizer’s portfolio set to lose patent exclusivity this decade.